Forepont Capital Partners is a venture capital firm established in 2014, headquartered in New York, with additional offices in London and Paris. The firm focuses on investing in early-stage start-ups, primarily in series A and B rounds, with a particular emphasis on sectors such as healthcare, biotechnology, medtech, life sciences, and technology. Forepont aims to support innovative initiatives by providing scientific, technological, financial, and operational assistance to its portfolio companies, which include those involved in genomics, imaging, biomarkers, systems therapeutics, data analytics, wearables, and mobile applications. By leveraging its expertise and a global network, Forepont Capital Partners seeks to create impactful investments across the United States and Europe.
Okeiro offers an AI platform for chronic disease and transplant care, enabling early detection, monitoring, and treatment.
AlterDiag
Seed Round in 2025
AlterDiag mission is to develop and commercialize innovative lateral flow immunochromatographic tests using technologies like single-chain variable fragment antibodies.
GPN Vaccines
Series B in 2024
GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.
GPN Vaccines
Series A in 2023
GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.
Precision Neuroscience
Series B in 2023
Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.
Mobius Biomedical
Venture Round in 2022
Mobius Biomedical plans to bring unprecedented efficiencies to the development and manufacturing of biologics and biosimilars, and reduce their cost by over 90% at commercial scale. The Company has developed new design, new process and new equipment to drastically reduce the capex, opex and facility footprint of manufacturing plants while maintaining the purity, throughput and efficiency at commercial scale.
Precision Neuroscience
Series A in 2021
Precision Neuroscience is a company focused on developing advanced brain-computer interface technology aimed at offering innovative treatments for the approximately one billion individuals worldwide affected by neurological disorders. Founded in 2021 and based in New York, the company's technology is characterized by its minimally invasive design, safety for removal, and capacity for processing substantial data. This platform enables medical professionals to establish a direct connection between the human brain and artificial intelligence, potentially transforming the landscape of neurological care.
GPN Vaccines
Series A in 2020
GPN Vaccines is a clinical-stage biotechnology company focused on developing a vaccine against Streptococcus pneumoniae, a leading cause of pneumonia, bacteremia, meningitis, and otitis media. The company's innovative vaccine utilizes a gamma-irradiation process to inactivate and kill the bacteria while preserving the surface protein antigens. This method aims to enhance the immune response, offering improved protection against pneumococcal infections. GPN Vaccines seeks to address a critical public health need by providing a vaccine that can significantly reduce the impact of this serious bacterial pathogen.
BayBridgeDigital
Series A in 2018
BayBridge Digital is a hybrid digital firm focused on driving digital transformation for businesses by leveraging design-led approaches and the Salesforce ecosystem. The company develops software that enhances sales, marketing agility, and operational efficiency, which in turn accelerates cloud and digital adoption across various industries. Through its services, BayBridge Digital aims to create new growth opportunities and deliver significant business value, ultimately improving customer experiences and increasing sales. The firm operates on three foundational pillars that support its mission to bridge traditional business practices with the digital landscape.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.